Fluorescent retinoid X receptor ligands for fluorescence polarization assay

Shoya Yamada, Fuminori Ohsawa, Shuji Fujii, Ryosuke Shinozaki, Makoto Makishima, Hirotaka Naitou, Shuichi Enomoto, Akihiro Tai, Hiroki Kakuta

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Retinoid X receptor (RXR) agonists are candidate agents for the treatment of metabolic syndrome and type 2 diabetes via activation of peroxisome proliferator-activated receptor (PPAR)/RXR or liver X receptor (LXR)/RXR-heterodimers, which control lipid and glucose metabolism. Reporter gene assays or binding assays with radiolabeled compounds are available for RXR ligand screening, but are unsuitable for high-throughput screening. Therefore, as a first step towards stabilizing a fluorescence polarization (FP) assay system for high-throughput RXR ligand screening, we synthesized fluorescent RXR ligands by modification of the lipophilic domain of RXR ligands with a carbostyril fluorophore, and selected the fluorescent RXR agonist 6-[ethyl(1-isobutyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-7-yl)amino] nicotinic acid 8d for further characterization. Compound 8d showed FP in the presence of RXR and the FP was decreased in the presence of the RXR agonist LGD1069 (2). This compound should be a lead compound for use in high-throughput assay systems for screening RXR ligands.

Original languageEnglish
Pages (from-to)5143-5146
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume20
Issue number17
DOIs
Publication statusPublished - Sep 1 2010

Fingerprint

Retinoid X Receptors
Fluorescence Polarization
Assays
Fluorescence
Polarization
Ligands
Screening
Throughput
High-Throughput Screening Assays
Lead compounds
Peroxisome Proliferator-Activated Receptors
Fluorophores
Niacin
Medical problems
Reporter Genes
Lipid Metabolism
Metabolism
Liver
Type 2 Diabetes Mellitus
Genes

Keywords

  • Carbostyril
  • Fluorescence polarization
  • Molecular design
  • Retinoid X receptor

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Fluorescent retinoid X receptor ligands for fluorescence polarization assay. / Yamada, Shoya; Ohsawa, Fuminori; Fujii, Shuji; Shinozaki, Ryosuke; Makishima, Makoto; Naitou, Hirotaka; Enomoto, Shuichi; Tai, Akihiro; Kakuta, Hiroki.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 20, No. 17, 01.09.2010, p. 5143-5146.

Research output: Contribution to journalArticle

Yamada, S, Ohsawa, F, Fujii, S, Shinozaki, R, Makishima, M, Naitou, H, Enomoto, S, Tai, A & Kakuta, H 2010, 'Fluorescent retinoid X receptor ligands for fluorescence polarization assay', Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 17, pp. 5143-5146. https://doi.org/10.1016/j.bmcl.2010.07.011
Yamada, Shoya ; Ohsawa, Fuminori ; Fujii, Shuji ; Shinozaki, Ryosuke ; Makishima, Makoto ; Naitou, Hirotaka ; Enomoto, Shuichi ; Tai, Akihiro ; Kakuta, Hiroki. / Fluorescent retinoid X receptor ligands for fluorescence polarization assay. In: Bioorganic and Medicinal Chemistry Letters. 2010 ; Vol. 20, No. 17. pp. 5143-5146.
@article{2cdda909634c4c499542a9d607f7bda6,
title = "Fluorescent retinoid X receptor ligands for fluorescence polarization assay",
abstract = "Retinoid X receptor (RXR) agonists are candidate agents for the treatment of metabolic syndrome and type 2 diabetes via activation of peroxisome proliferator-activated receptor (PPAR)/RXR or liver X receptor (LXR)/RXR-heterodimers, which control lipid and glucose metabolism. Reporter gene assays or binding assays with radiolabeled compounds are available for RXR ligand screening, but are unsuitable for high-throughput screening. Therefore, as a first step towards stabilizing a fluorescence polarization (FP) assay system for high-throughput RXR ligand screening, we synthesized fluorescent RXR ligands by modification of the lipophilic domain of RXR ligands with a carbostyril fluorophore, and selected the fluorescent RXR agonist 6-[ethyl(1-isobutyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-7-yl)amino] nicotinic acid 8d for further characterization. Compound 8d showed FP in the presence of RXR and the FP was decreased in the presence of the RXR agonist LGD1069 (2). This compound should be a lead compound for use in high-throughput assay systems for screening RXR ligands.",
keywords = "Carbostyril, Fluorescence polarization, Molecular design, Retinoid X receptor",
author = "Shoya Yamada and Fuminori Ohsawa and Shuji Fujii and Ryosuke Shinozaki and Makoto Makishima and Hirotaka Naitou and Shuichi Enomoto and Akihiro Tai and Hiroki Kakuta",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.bmcl.2010.07.011",
language = "English",
volume = "20",
pages = "5143--5146",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - Fluorescent retinoid X receptor ligands for fluorescence polarization assay

AU - Yamada, Shoya

AU - Ohsawa, Fuminori

AU - Fujii, Shuji

AU - Shinozaki, Ryosuke

AU - Makishima, Makoto

AU - Naitou, Hirotaka

AU - Enomoto, Shuichi

AU - Tai, Akihiro

AU - Kakuta, Hiroki

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Retinoid X receptor (RXR) agonists are candidate agents for the treatment of metabolic syndrome and type 2 diabetes via activation of peroxisome proliferator-activated receptor (PPAR)/RXR or liver X receptor (LXR)/RXR-heterodimers, which control lipid and glucose metabolism. Reporter gene assays or binding assays with radiolabeled compounds are available for RXR ligand screening, but are unsuitable for high-throughput screening. Therefore, as a first step towards stabilizing a fluorescence polarization (FP) assay system for high-throughput RXR ligand screening, we synthesized fluorescent RXR ligands by modification of the lipophilic domain of RXR ligands with a carbostyril fluorophore, and selected the fluorescent RXR agonist 6-[ethyl(1-isobutyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-7-yl)amino] nicotinic acid 8d for further characterization. Compound 8d showed FP in the presence of RXR and the FP was decreased in the presence of the RXR agonist LGD1069 (2). This compound should be a lead compound for use in high-throughput assay systems for screening RXR ligands.

AB - Retinoid X receptor (RXR) agonists are candidate agents for the treatment of metabolic syndrome and type 2 diabetes via activation of peroxisome proliferator-activated receptor (PPAR)/RXR or liver X receptor (LXR)/RXR-heterodimers, which control lipid and glucose metabolism. Reporter gene assays or binding assays with radiolabeled compounds are available for RXR ligand screening, but are unsuitable for high-throughput screening. Therefore, as a first step towards stabilizing a fluorescence polarization (FP) assay system for high-throughput RXR ligand screening, we synthesized fluorescent RXR ligands by modification of the lipophilic domain of RXR ligands with a carbostyril fluorophore, and selected the fluorescent RXR agonist 6-[ethyl(1-isobutyl-2-oxo-4-trifluoromethyl-1,2-dihydroquinolin-7-yl)amino] nicotinic acid 8d for further characterization. Compound 8d showed FP in the presence of RXR and the FP was decreased in the presence of the RXR agonist LGD1069 (2). This compound should be a lead compound for use in high-throughput assay systems for screening RXR ligands.

KW - Carbostyril

KW - Fluorescence polarization

KW - Molecular design

KW - Retinoid X receptor

UR - http://www.scopus.com/inward/record.url?scp=77955661848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955661848&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2010.07.011

DO - 10.1016/j.bmcl.2010.07.011

M3 - Article

VL - 20

SP - 5143

EP - 5146

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 17

ER -